Multiple hypoxia- and metabolism-related pathways

Multiple hypoxia- and metabolism-related pathways refers to a broad set of cellular mechanisms, primarily governed by Hypoxia-Inducible Factors (HIFs), that coordinate the response to reduced oxygen availability and the subsequent shift in energy metabolism (Semenza, 2012; Wang & Semenza, 1995). These pathways are critical for maintaining cellular homeostasis but are frequently dysregulated in pathological states such as solid tumors, where they promote angiogenesis, survival, and a shift toward aerobic glycolysis, known as the Warburg effect (Vander Heiden et al., 2009). Key components within these pathways include enzymes like Lactate Dehydrogenase A (LDHA) and transporters like Glucose Transporter 1 (GLUT1), which are often overexpressed to meet the high metabolic demands of cancer cells (Denko, 2008). Pharmacological intervention typically targets specific nodes within these pathways, such as HIF-2α inhibitors like Belzutifan for cancer or Prolyl Hydroxylase (PHD) inhibitors like Roxadustat to treat anemia (Jonasch et al., 2021; Chen et al., 2019). Given the systemic importance of oxygen sensing and energy production, therapeutic challenges include managing off-target effects on normal tissue metabolism and the risk of excessive erythropoiesis (Haase, 2013). Biomarkers such as HIF-1α expression and serum lactate levels are frequently employed to monitor pathway activity and therapeutic efficacy (Vander Heiden et al., 2009).

Other names

Hypoxia-inducible factor signaling pathwayMetabolic reprogrammingWarburg effectOxygen-sensing pathwaysHIF-mediated transcription

Drugs targeting these pathways typically act by inhibiting HIF-2α dimerization, inhibiting prolyl hydroxylase enzymes to stabilize HIF-alpha subunits, or modulating key glycolytic enzymes and transporters to disrupt metabolic adaptation.